

Evonik establishes Global Competence Network for Cell Culture Solutions

2 October 2024

- First point of contact for partners seeking to manufacture cell culture-based therapies more efficiently
- Draws on multidisciplinary team of experts
- Drives the development of system solutions to address upstream challenges in cell culture

Main press contact

Janusz Berger
Head of Market Communications
Health Care
Phone +49 6151 18-4984
janusz.berger@evonik.com

Alternative press contact

Holger Seier
Research & Development
Phone +49 2365 49 88732
holger.seier@evonik.com

Essen, Germany. Evonik has established a new global network to develop system solutions that address upstream challenges in cell culture. The Global Competence Network for Cell Culture Solutions brings together a multidisciplinary team of business, application technology and research and development experts in chemistry, cell biology, bioprocessing and media optimization across Asia, Europe and the Americas. The goal of the network is to empower customers to manufacture cell culture-based therapies more efficiently.

Optimizing cell culture media is a key strategy to ensure high yields and product quality for biopharmaceuticals. The new network will increase Evonik's offering of system solutions for cell culture media. It also forms part of the company's recently introduced "Advance Precision Biosolutions" innovation growth area within the life sciences division, Nutrition & Care. The growth area includes focusing on the development of biosurfactants, as well as cosmetic and pharmaceutical solutions that improve people's health and quality of life, save resources and protect ecosystems.

"With our new competence network, we go beyond by cross-connecting skills, driving innovation and sustainably propelling healthcare into the future," said Hans Henning Wenk, Vice President R&D for the Health Care business at Evonik.

Evonik's Global Competence Network for Cell Culture Solutions works with partners to address upstream challenges in cell culture such as process intensification and scalability. The network draws on a strong ingredient portfolio that includes the cQrex® peptides, plant-based cholesterol (PhytoChol®) and specialty carbohydrates,

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Maike Schuh, Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

as well as R&D, formulation and process expertise. The network will be the primary resource for customers in need of system solutions that enhance their media and processes.

The network has multiple locations worldwide, with teams in Germany focusing primarily on CHO cell culture and analytics, complemented by cell and gene therapy application development in Singapore. A recent addition is an **Innovation Satellite** in Cambridge (MA) in the U.S., where Evonik's strategic innovation unit and business incubator, Creavis, will focus on R&D for nucleic acid-based medicines and cell culture solutions.

System solutions are tailored offerings that integrate products, technologies and services, and often have proven sustainability benefits. By focusing on system solutions, Evonik is positioning itself as a partner that supports customers from ideation to the finished product, enabling them to bring differentiated products to market more rapidly.

Further Information

More about Evonik's [Cell Culture Solutions](#)

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

About Creavis

Creavis is Evonik's strategic innovation unit and business incubator. For more than 20 years, it has paved the way for new technologies and innovative business models to make the future a good place to live. Around 200 employees across the world develop sustainable solutions to key challenges resulting from climate change and population growth. In this way, they drive forward new commercial ecosystems and value chains. <https://www.creavis.com/en/about-creavis>.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.